A Phase 1 interventional study of MM-121 and Irinotecan in Colorectal Cancer, Squamous Cell Head and Neck Cancer and Non-small Cell Lung Cancer, sponsored by Merrimack Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-08.
Sponsored by Merrimack Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 105th largest by enrollment of the 185 interventional ones that give a count, is one of 4 that started in 2011, is one of 19 in phase 1, and was the 93rd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Verastem, Inc. · Sites in United States, Australia
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 131 · Phase 3 33 · Phase 4 4
First in 1999; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 185 interventional studies. Of the 108 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 187 have an industry lead sponsor. The 10 most frequent:
Merrimack Pharmaceuticals is the lead sponsor of 25 studies on the registry; none are open to participants now.
Merrimack Pharmaceuticals has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing cetuximab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06226857Phase 3City Clinical Oncology Hospital No 1Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07659795Verastem, Inc.A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and irinotecan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
increasing doses of weekly MM-121 + weekly cetuximab
Drug: MM-121 · Drug: Cetuximab
increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
Drug: MM-121 · Drug: Irinotecan · Drug: Cetuximab
escalating doses MM-121 IV QW
Also known as: Seribantumab, SAR256212
180 mg/m2 IV Q2W
Also known as: Camptosar
escalating doses cetuximab IV QW
Also known as: Erbitux
Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination
To establish the safety of escalating doses of MM-121 in combination with cetuximab or in combination with cetuximab and irinotecan in order to determine the recommended phase 2 dose.. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.
Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks
To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses
Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2
Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks
To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan
Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2
Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks
Objective Response Rate
To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \>20% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline. Objective Response is presented as the total # patients with PR or CR.
Time frame: Patients were assessed for objective response from time of first dose through treatment termination, the longest treatment duration being 48.1 weeks
Pharmacokinetics
Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the maximum observed concentration (Cmax). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)
Time frame: Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121
Pharmacokinetic Parameters of MM-121
Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the AUClast. Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)
Time frame: Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121
Immunogenicity
Samples were collected to determine the presence of an immunologic reaction to MM-121 (i.e. human anti-human antibodies).
Time frame: Samples were collected for all patients pre-dose on all cycles for duration of treatment, the longest of which was 48.1 weeks, and a collection was made post-infusion in any case of infusion reaction
| Milestone | Part 1: Cohort 1 | Part 1: Cohort 2a | Part 1: Cohort 2b | Part 1: Cohort 3a | Part 1: Cohort 3b | Part 1: Cohort 4 | Part 1: Expansion Cohort | Part 2: Cohort 1 | Part 2: Cohort 2 | Part 2: Expansion Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 4 | 3 | 3 | 4 | 4 | 8 | 6 | 4 | 4 |
| Completed | 8 | 4 | 3 | 3 | 4 | 4 | 8 | 6 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To establish the safety of escalating doses of MM-121 in combination with cetuximab or in combination with cetuximab and irinotecan in order to determine the recommended phase 2 dose.. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.
| participants reporting DLTs | Part 1: Cohort 1 | Part 1: Cohort 2a | Part 1: Cohort 2b | Part 1: Cohort 3a | Part 1: Cohort 3b | Part 1: Cohort 4 | Part 2: Cohort 1 | Part 2: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2
| mg/kg | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan |
|---|---|---|
| MM-121 loading dose | 40 | NA |
| MM-121 maintenance dose | 20 | 20 |
Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2
| mg/m2 | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan |
|---|---|---|
| Cetuximab loading dose | 400 | 400 |
| Cetuximab maintenance dose | 250 | 250 |
| Irinotecan | NA | 180 |
To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \>20% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline. Objective Response is presented as the total # patients with PR or CR.
| participants with objective response | Part 1: Cohort 1 | Part 1: Cohort 2a | Part 1: Cohort 2b | Part 1: Cohort 3a | Part 1: Cohort 3b | Part 1: Cohort 4 | Part 1: Expansion Cohort | Part 2: Cohort 1 | Part 2: Cohort 2 | Part 2: Expansion Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the maximum observed concentration (Cmax). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)
| ug/mL | Part 1: 12 mg/kg | Part 1: 20 mg/kg | Part 1: 40/20 mg/kg | Part 2: 20 mg/kg | Part 2: 40/20 mg/kg |
|---|---|---|---|---|---|
| Pharmacokinetics | 316.8 ± 23.6 | 611.0 ± 45.8 | 794.1 ± 58.2 | 505.8 ± 10.2 | 1278.2 ± 25 |
Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the AUClast. Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)
| hr* ug/mL | Part 1: 12 mg/kg | Part 1: 20 mg/kg | Part 1: 40/20 mg/kg | Part 2: 20 mg/kg | Part 2: 40/20 mg/kg |
|---|---|---|---|---|---|
| Pharmacokinetic Parameters of MM-121 | 24190.5 ± 22.0 | 53063.1 ± 46.1 | 91111.9 ± 39.9 | 47681.5 ± 14.2 | 98387.7 ± 16.2 |
Samples were collected to determine the presence of an immunologic reaction to MM-121 (i.e. human anti-human antibodies).
| Measure | Part 1: Cohort 1 | Part 1: Cohort 2a | Part 1: Cohort 2b | Part 1: Cohort 3a | Part 1: Cohort 3b | Part 1: Cohort 4 | Part 1: Expansion Cohort | Part 2: Cohort 1 | Part 2: Cohort 2 | Part 2: Expansion Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunogenicity | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Collected over AEs were collected from a patient's first dose until 30 days after treatment termination. SAEs were collected from time of informed consent until 30 days after termination. If related, events could be reported at any time after termination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: MM-121 + Cetuximab | — | 15/34 (44.1%) | 34/34 (100%) |
| Part 2: MM-121 + Cetuximab + Irinotecan | — | 6/14 (42.9%) | 14/14 (100%) |
| Event | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan |
|---|---|---|
| DiarrheaGastrointestinal disorders | 1/34 | 2/14 |
| Intestinal ObstructionGastrointestinal disorders | 0/34 | 1/14 |
| NauseaGastrointestinal disorders | 0/34 | 1/14 |
| StomatitisGastrointestinal disorders | 0/34 | 1/14 |
| VomitingGastrointestinal disorders | 0/34 | 1/14 |
| Non-cardiac chest painGeneral disorders | 0/34 | 1/14 |
| Urinary Tract InfectionInfections and infestations | 0/34 | 1/14 |
| Pericardial effusionCardiac disorders | 1/34 | 1/14 |
| Cardiac ArrestCardiac disorders | 0/34 | 1/14 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/34 | 1/14 |
| Event | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan |
|---|---|---|
| DiarrheaGastrointestinal disorders | 17/34 | 13/14 |
| FatigueGeneral disorders | 22/34 | 9/14 |
| HypokalemiaMetabolism and nutrition disorders | 10/34 | 9/14 |
| NauseaGastrointestinal disorders | 8/34 | 8/14 |
| Dermatitis AcneformSkin and subcutaneous tissue disorders | 18/34 | 4/14 |
| HypomagnesemiaMetabolism and nutrition disorders | 18/34 | 5/14 |
| Decreased AppetiteMetabolism and nutrition disorders | 12/34 | 7/14 |
| Weight DecreasedInvestigations | 8/34 | 7/14 |
| DehydrationMetabolism and nutrition disorders | 0/34 | 6/14 |
| StomatitisGastrointestinal disorders | 9/34 | 5/14 |
| Age, Continuous(years) | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan | Total |
|---|---|---|---|
| Mean | 56.1 ± 14.19 | 56.6 ± 11.38 | 56.35 ± 12.79 |
| Sex: Female, Male(Participants) | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan | Total |
|---|---|---|---|
| Female | 13 | 9 | 22 |
| Male | 21 | 5 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 31 | 13 | 44 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 26 | 13 | 39 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Part 1: MM-121 + Cetuximab | Part 2: MM-121 + Cetuximab + Irinotecan | Total |
|---|---|---|---|
| United States | 34 | 14 | 48 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2011, a primary completion of Nov 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Seribantumab · Cetuximab